Form D · Biotechnology
Kyverna Therapeutics, Inc.
Emeryville, CA · CIK 0001994702
Offering snapshot reported Nov 7, 2023 · SEC filing
- Reported sold
- $152M Offering amount: $152M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 9, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 7, 2023 | Initial | $151,999,981 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-496597
Shares issued in partial consideration the licenses and rights granted to the Company by the investor.
Source: Form D, filed Nov 7, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dominic Borie | Executive |
| James Chung | Executive |
| Ian Clark | Director |
| Fred Cohen | Director |
| Ryan Jones | Executive |
| Brian Kotzin | Director |
| Steve Liapis | Director |
| Peter Maag | Director, Executive |
| Dan Spiegelman | Director |
| Beth Spiegelman | Director |
| Karen Walker | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5980 Horton Street Suite 550
Emeryville, CA, 94608
Emeryville, CA, 94608